NCT06822517 is a Phase 1, PHASE2 clinical trial of VENT-02 in Parkinson Disease, sponsored by Ventus Therapeutics U.S., Inc..

Who is sponsoring NCT06822517?

NCT06822517 is sponsored by Ventus Therapeutics U.S., Inc..

What drugs are being tested in NCT06822517?

Interventions in NCT06822517: VENT-02, Placebo.

What condition does NCT06822517 study?

NCT06822517 studies Parkinson Disease.

Is NCT06822517 still recruiting?

NCT06822517 is currently terminated. Last updated 29 October 2025.

Last reviewed 2025-10-29 · How we verify

NCT06822517

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease

Terminated Phase 1, PHASE2 Last updated 29 October 2025

What this trial tests

Phase 1, PHASE2 trial testing VENT-02 in Parkinson Disease in 29 participants. Terminated before completion.

Timeline

5 March 2025

Primary endpoint
9 October 2025

9 October 2025

Quick facts

Lead sponsor	Ventus Therapeutics U.S., Inc.
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	29
Start date	5 March 2025
Primary completion	9 October 2025
Estimated completion	9 October 2025
Sites	23 locations across United States

Drugs / interventions tested

VENT-02 — full drug profile →
Placebo

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Ventus Therapeutics U.S., Inc. — full company profile →

Who can join

Adults 45 to 90, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease. The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose. Approximately 30 patients will be randomized into 1 of the 2 treatment arms.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.
Noh MY, Kwon HS, Kwon MS, Nahm M, et al · · 2025 · cited 24× · PMID 40640892 · DOI 10.1186/s13024-025-00867-4
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497
Plant natural products targeting NLRP3 inflammasome in Parkinson's disease: Molecular activation and regulation to therapeutics.
Lu H, Zeng F, Sun J, Li B, et al · · 2026 · PMID 41907443 · DOI 10.1016/j.isci.2026.115257
Microglia heterogeneity and therapeutic strategies in Parkinson's disease.
Tian J, Liu X, Wang Z, Shi X, et al · · 2026 · PMID 41727462 · DOI 10.3389/fimmu.2026.1739341
Biomarker Discovery in Wilson's Disease-A Path Toward Improved Diagnosis and Management: A Comprehensive Review.
Wolska M, Wicik Z, Ahmadova S, Mirowska-Guzel D, et al · · 2025 · PMID 40531364 · DOI 10.1007/s12035-025-05143-6

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06822517 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ventus Therapeutics U.S., Inc.
Last refreshed: 29 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06822517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing